Fig. 6
From: THOR is a targetable epigenetic biomarker with clinical implications in breast cancer
Targeted THOR demethylation using CRISPR–dCas9 and a peptide-repeat-based system. Demethylation activities quantified by MiSeq for both A active (TET_MO) and B a catalytically dead TET1 (IN_MO) are shown. 48 h post-transfection cells were sorted by FACS to select GFP-expressing cells and submitted to bisulfite treatment. The genomic coordinates of each CpG site and the distance of the first position of each amplicon in relation to the transcription start site is shown. C TETg7_MO and TETg5 + g7 induced significant targeted demethylation of THOR within the hTERT promoter. CpG methylation was calculated as the mean percentage of all CpG sites. Bars represent the mean of 3 independent experiments ± SD. P values were determined using two-tailed, unpaired Student’s t test. *P < 0.05; **P < 0.01; ***P < 0.001